November 15, 2021

Mvasi® (bevacizumab-awwb) has received a new indication to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug, manufactured by Amgen, is a biosimilar for Genentech’s Avastin® (bevacizumab).

  • Under the new indication, Mvasi is FDA approved for use in combination with:
    • Carboplatin and paclitaxel, followed by Mvasi a single agent, for stage III or IV disease following initial surgical resection;
    • Paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease in patients who have received no more than two prior chemotherapy regimens; or
    • Carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Mvasi as a single agent, for platinum-sensitive recurrent disease.
  • The new indication mirrors an FDA-approved indication for Mvasi’s reference product, Avastin.
  • Recommend dosing and duration of treatment under the indication is based on individual patient factors such as treatment history, chemotherapy regimen, and disease state. Mvasi is administered by a healthcare provider via intravenous infusion over the course of 30-90 minutes, based on treatment tolerance.
  • Mvasi first received U.S. FDA approval in 2017.
January 3, 2022

FDA Expands Comirnaty Authorization to Prevent COVID-19

Read More
December 23, 2021

Merck’s COVID-19 Antiviral Granted Emergency Use Authorization

Read More
December 22, 2021

FDA Authorizes First Oral Antiviral for COVID-19

Read More
December 20, 2021

Xarelto Approved to Treat and Prevent Blood Clots in Children

Read More